Zacks: Analysts Expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) Will Announce Quarterly Sales of $150.25 Million

Share on StockTwits

Wall Street analysts expect that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will announce $150.25 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Ionis Pharmaceuticals’ earnings, with estimates ranging from $133.80 million to $181.50 million. Ionis Pharmaceuticals posted sales of $145.40 million during the same quarter last year, which suggests a positive year-over-year growth rate of 3.3%. The firm is expected to report its next quarterly earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year sales of $798.18 million for the current fiscal year, with estimates ranging from $738.15 million to $934.00 million. For the next fiscal year, analysts expect that the business will report sales of $951.62 million, with estimates ranging from $641.54 million to $1.81 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.26. The business had revenue of $164.00 million for the quarter, compared to analyst estimates of $145.31 million. Ionis Pharmaceuticals had a return on equity of 38.70% and a net margin of 49.90%. The company’s revenue was up 39.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.29) EPS.

Several equities analysts have recently weighed in on IONS shares. BidaskClub raised Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. TheStreet lowered Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a research note on Thursday, August 8th. Evercore ISI set a $76.00 price objective on Ionis Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, August 7th. BMO Capital Markets reduced their price objective on Ionis Pharmaceuticals from $96.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 24th. Finally, Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 31st. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company’s stock. Ionis Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $75.40.

Shares of NASDAQ IONS traded up $0.64 during midday trading on Friday, hitting $62.74. The stock had a trading volume of 810,264 shares, compared to its average volume of 986,185. The company has a market capitalization of $8.25 billion, a price-to-earnings ratio of 21.20 and a beta of 1.95. Ionis Pharmaceuticals has a 1-year low of $43.27 and a 1-year high of $86.58. The company has a quick ratio of 9.93, a current ratio of 10.01 and a debt-to-equity ratio of 0.45. The company has a fifty day moving average price of $62.64 and a 200 day moving average price of $67.89.

In related news, CEO Stanley T. Crooke sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $70.25, for a total transaction of $702,500.00. Following the transaction, the chief executive officer now directly owns 79,634 shares of the company’s stock, valued at approximately $5,594,288.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Stanley T. Crooke sold 22,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $71.52, for a total value of $1,573,440.00. Following the transaction, the chairman now directly owns 79,634 shares in the company, valued at $5,695,423.68. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Whittier Trust Co. lifted its position in Ionis Pharmaceuticals by 283.0% during the 2nd quarter. Whittier Trust Co. now owns 383 shares of the company’s stock worth $25,000 after acquiring an additional 283 shares in the last quarter. CWM LLC lifted its position in Ionis Pharmaceuticals by 361.4% during the 2nd quarter. CWM LLC now owns 406 shares of the company’s stock worth $26,000 after acquiring an additional 318 shares in the last quarter. Ellis Investment Partners LLC acquired a new position in Ionis Pharmaceuticals during the 2nd quarter worth approximately $32,000. Rehmann Capital Advisory Group lifted its position in Ionis Pharmaceuticals by 41.3% during the 2nd quarter. Rehmann Capital Advisory Group now owns 592 shares of the company’s stock worth $38,000 after acquiring an additional 173 shares in the last quarter. Finally, Advisory Services Network LLC lifted its position in Ionis Pharmaceuticals by 38.5% during the 2nd quarter. Advisory Services Network LLC now owns 907 shares of the company’s stock worth $58,000 after acquiring an additional 252 shares in the last quarter. 89.05% of the stock is currently owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

See Also: Equity Income

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.